Pulmonary mucormycosis
ICD-10 B46.2 is a billable code used to indicate a diagnosis of pulmonary mucormycosis.
Pulmonary mucormycosis is a severe fungal infection caused by fungi of the Mucorales order, primarily affecting immunocompromised individuals. This condition is characterized by the invasion of the lungs by these opportunistic pathogens, leading to necrotizing pneumonia and potentially systemic dissemination. Patients often present with symptoms such as fever, cough, chest pain, and hemoptysis. The infection is particularly prevalent in individuals with underlying conditions such as diabetes mellitus, hematological malignancies, or those undergoing immunosuppressive therapy. Diagnosis typically involves imaging studies, such as CT scans, and microbiological cultures or histopathological examination of lung tissue. Prompt antifungal treatment is critical, with agents such as amphotericin B being the first line of therapy, often supplemented with surgical debridement of necrotic tissue. The prognosis is poor without timely intervention, making early recognition and treatment essential.
Detailed clinical notes on the patient's immunocompromised status, symptoms, diagnostic tests, and treatment plans.
Patients with hematological malignancies presenting with respiratory symptoms and fever.
Documentation must include the type of immunosuppression and any prior antifungal treatments.
Thorough pulmonary function tests, imaging results, and treatment response notes.
Patients with chronic lung disease who develop acute respiratory distress.
Need to document the extent of lung involvement and any surgical interventions performed.
Used when lung tissue is biopsied to confirm mucormycosis.
Pathology report must indicate the presence of Mucorales.
Infectious disease specialists should ensure that the biopsy is appropriately indicated.
Common symptoms include fever, cough, chest pain, and hemoptysis, particularly in immunocompromised patients.
Diagnosis typically involves imaging studies, microbiological cultures, and histopathological examination of lung tissue.
The first-line treatment is usually amphotericin B, often in conjunction with surgical debridement of affected tissue.
